Teva suffers EpiPen generic setback after FDA rejection

The release of Teva Pharmaceuticals generic for the anaphylaxis treatment, EpiPen (epinephrine), is now expected to be severely delayed after the FDA rejected its version, flagging “major deficiencies”.
The Israeli-based company had originally planned to bring the auto-injector to market in 2017, but this no longer looks to be the case. EpiPen is used to treat anaphylaxis. It is a boost of adrenaline that helps to remedy a serious allergic reaction that is rapid in onset, and may cause death.
The firm issued a notice, stating: "Teva received a complete response letter on February 23 relating to its epinephrine ANDA in which the FDA identified certain major deficiencies. Teva is evaluating the CRL and intends to submit a response. Due to the major nature of the CRL, Teva expects that its epinephrine product will be significantly delayed and that any launch will not take place before 2017.”
This news, however, is expected to be a major boost for Mylan, which markets EpiPen in the US. Analysts had predicted that the company would lose out on $200m worth of sales to Teva when its generic was due to become available in 2017.
This is the second time in a few months that Mylan has received such a boost, after Sanofi’s rival product Auvi-Q was forced into a recall due to suspected device malfunctions.
Sean Murray
- Login or register to post comments
- Printer-friendly version
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches
Related content
- Teva announces FDA approval for asthma injection, Cinqair
- FDA expands indication of Teva's Trisenox for acute promyelocytic leukaemia
- FDA unveils guidelines to help generic medical device versions reach the market
- Teva scores expanded indication for Austedo in tardive dyskinesia
- FDA approves first generic versions of Lilly's ADHD drug